Drugs / B/F/TAF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03547908 | May 2018 → Feb 2022 | — | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547908 ↗ |
| Known as | bictegravir/emtricitabine/tenofovir alafenamide | “The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus...” NCT03547908 ↗ |
| Route | Oral | “50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food” NCT03547908 ↗ |